CVS Health is set to release its latest quarterly results on Feb. 10. Expectations are high due to past earnings beats. However, the recent proposed Medicare Advantage payment rates could impact the company’s 2026 guidance and lead to a negative market response.

Investors are watching closely as CVS Health navigates potential headwinds from Medicare changes. Despite recent volatility, CVS’ diverse business segments may help offset challenges and maintain its long-term growth potential.

Compared to UnitedHealth, CVS Health’s valuation appears more reasonable, providing room for potential upside if results exceed expectations. The company’s strategic efforts and diversified revenue streams could support its resilience in the face of regulatory changes and market shifts.

Read more at Yahoo Finance: Should You Buy CVS Health Stock Before Feb. 10?